Physician profile
Imran P Haque
NPI 1134107022
$16,942.96
in general payments reported to CMS, 2019-2025
84 companies · $2,111 in 2025
The $2,111 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,627 · 2020: $2,249 · 2021: $2,296 · 2022: $2,810 · 2023: $2,441 · 2024: $2,409 · 2025: $2,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,919 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,919.02 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,807.76 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,746.74 | 2020-2025 | |
| Lilly USA, LLC | $1,349.87 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,213.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Teva Pharmaceuticals USA, INC. | $748.17 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $747.88 | 2019-2025 | |
| Alkermes, INC. | $671.10 | 2022-2024 | Aristada, Lybalvi |
| Glaxosmithkline, LLC. | $539.10 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $483.77 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $458.67 | 2019-2025 | |
| Eisai INC. | $398.25 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $375.53 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $313.62 | 2019-2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $312.97 | 2019-2025 | Rexulti, Nuedexta |
| Neurocrine Biosciences, INC. | $304.71 | 2021-2023 | Ingrezza |
Show all 84 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Haque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.